We are looking to cooperate with experts to be engaged in R&D expert review of VC projects associated with new developments of pharmaceuticals and technologies in the field of medicine.
Cooperation with external experts is subject to a paid basis.
To participate in R&D expert review activities the experts must obtain accreditation (see below).
The work with experts is based on the following:
Accredited experts subject to the expert review shall assess a scientific value of the VC project under review for potential investment pursuant to standard terms of reference. Impersonal consolidated expert report shall be generated following the results of assessment.
For more information concerning R&D expert review process in RusnanoMedInvest, LLC please go here.
Major expert enrollment criteria:
To join our expert team:
The right to verify information provided is vested in RusnanoMedInvest, LLC.
Please note that filled form is not subject to instant accreditation as an expert.
The contract on the expertise is offered by D-Pharma LTD – the management company of RusnanoMedInvest.
Pfizer Inc, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio. The deal will enable Pfizer and NovaMedica to improve the health of patients in Russia and modernize the Russian pharmaceutical industry.
26 April 2017
25 April 2017